PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 2005 January 17; 92(1): 113–119.
Published online 2004 December 7. doi:  10.1038/sj.bjc.6602244
PMCID: PMC2361744

Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma

Abstract

The peroxisome proliferator-activated receptors (PPARs) belong to a subclass of nuclear hormone receptor that executes important cellular transcriptional functions. Previous studies have demonstrated the expression of PPARγ in several tumours including colon, breast, bladder, prostate, lung and stomach. This study demonstrates the relative expression of PPARγ in normal ovaries and different pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes. A total of 56 ovarian specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using immunohistochemistry. Immunoreactive PPARγ was not expressed in normal ovaries. Out of eight benign and 10 borderline tumours, only one tumour in each group showed weak cytoplasmic PPARγ expression. In contrast, 26 out of 28 carcinomas studied were positive for PPARγ expression with staining confined to cytoplasmic and nuclear regions. An altered staining pattern of PPARγ was observed in high-grade ovarian tumours with PPARγ being mostly localized in the nuclei with little cytoplasmic immunoreactivity. On the other hand, predominant cytoplasmic staining was observed in lower-grade tumours. Significantly increased PPARγ immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours (χ2=48.80, P<0.001). Western blot analyses showed significant elevation in the expression of immunoreactive PPARγ in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P<0.01). These findings suggest an involvement of PPARγ in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.

Keywords: peroxisome proliferator-activated receptor, ovarian cancer, immunohistochemistry, nuclear and cytoplasmic staining

Epithelial ovarian cancer is the leading cause of death from gynaecologic malignancies. As ovarian cancer produces few specific symptoms in the early stage, most women present with advanced stage disease where the prognosis is poor (Jacobs and Menon, 2004). Greater than 90% of epithelial ovarian cancer arises from the transformation of ovarian surface epithelium (Choi and Auersperg, 2003). Hence, comparison between the protein expression profile of normal and transformed ovaries is important to identify and understand the molecules involved in the onset and progression of the disease.

The peroxisome proliferator-activated receptors (PPARs) comprise an important subfamily of the nuclear hormone receptor superfamily. Three isoforms have been identified, PPARα, PPARβ and PPARγ. Each exhibits distinct patterns of tissue distribution and ligand specificity (Kersten et al, 2000). They share common structural features, which include an amino-terminal modulatory domain, a DNA-binding domain and a carboxyl-terminal ligand-binding domain (Moras and Gronemeyer, 1998). PPARα is present in high levels in the kidney, heart, muscle, liver, brown adipose tissue and gut (Kliewer et al, 1994), whereas PPARβ is ubiquitously expressed throughout the body (Kliewer et al, 1994). PPARγ is highly expressed in adipose tissue, and is also present in other tissues including the muscle, liver, heart, adrenal gland, spleen and placenta (Asami-Miyagishi et al, 2004; Feingold et al, 2004).

The PPARs are ligand-dependent transcription factors that regulate target gene expression by binding to specific peroxisome proliferator response elements (PPREs) in enhancer sites of target genes (Berger and Moller, 2002). Each receptor binds its PPREs as a heterodimer with a retinoid X receptor. Upon ligand activation, conformational rearrangement of PPARγ expresses transcriptional coactivator binding sites. Recruitment of coactivators involves transcription of genes implicated in the regulation of cell differentiation and activation pathways (Berger and Moller, 2002).

In cancer biology, PPARγ is the most intensively studied PPAR isoform. It is expressed in high levels in different cancer including colon (Bull, 2003), breast (Jiang et al, 2003), bladder (Yoshimura et al, 2003), prostate (Smith and Kantoff, 2002), head and neck (Jaeckel et al, 2001), cervical (Han et al, 2003) and endometrial cancer (Tong et al, 2000). Recent studies have demonstrated that ligand activation of PPARγ receptor is involved in adipocyte (Seo et al, 2004) and tumour cell differentiation (Gauthier et al, 2003). In colon cancer, ligand activation of PPARγ-mediated differentiation of certain colon cancer cells results in the upregulation of tumour suppressor genes caveolin 1 and 2 (Burgermeister et al, 2003) and repression of cyclin D1 expression (Wang et al, 2003). Similarly, in vitro studies in prostate cancer cells, which express fairly abundant PPARγ, can result in the differentiation of prostate cancer cells and downregulation of androgen-stimulated PSA production (Hisatake et al, 2000). These findings have potentially important functional implication in the context of cancer cell differentiation therapy and multidrug resistance. Recently, Her2 has been shown to regulate PPAR expression (Yang et al, 2003). The ligands for PPARγ have been shown to increase the expression of BRCA 1 protein in human breast cancer cells (Pignatelli et al, 2003), indicating that PPARγ plays a crucial role in BRCA1 regulatory pathways involved in the pathogenesis of breast and sporadic ovarian cancer.

To our knowledge, a role for PPARγ in ovarian cancer development or function has not been described. In this study, we evaluated immunoreactive PPARγ protein expression in different pathological grades and subtypes of human epithelial ovarian tumours. We show that ovarian tumours express PPARγ and that expression is significantly higher in malignant tumours compared to benign tumours and normal ovaries. We also demonstrate that PPARγ expression pattern alters in high-grade ovarian tumours, implicating an important role for PPARγ in the progression of ovarian malignancy.

MATERIALS AND METHODS

Antibody and reagents

Mouse monoclonal and rabbit polyclonal antibodies against PPARγ were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Mouse IgG1 was obtained from Sigma (Sigma, St Louis, MO, USA). Immunoperoxidase secondary detection system was obtained from Chemicon International (Temecula, USA). ECL Western blotting detection reagents and analysis system were supplied by Amersham Biosciences (Amersham, UK).

Immunohistochemistry

The study was approved by the Research and Human Ethics Committee (HEC#02/30) of the Royal Women's Hospital, Melbourne, Australia. Human ovarian tumour tissues were collected at the time of surgical cytoreduction with the informed consent of the patients. Patient information is presented in Table 1 . Normal ovaries for control comparison were collected from patients undergoing surgery as a result of suspicious ultrasound, from prophylactic oophorectomy specimens. The pathology diagnosis and tumour grade was evaluated by two staff pathologists in the Department of Pathology, the Royal Women's Hospital, Melbourne, Australia. The classification of the tumours was performed as part of the clinical diagnosis according to the method described by Silverberg (2000). Surgically removed samples were fixed in 10% formalin and embedded in paraffin. Tissues for Western blot were snap frozen in liquid nitrogen and stored at −80°C until needed.

Table 1
Description of ovarian cancer patients participating in the study

Paraffin-embedded ovarian tissues were cut at 4 μm thickness and deparaffinised with xylene and rehydrated using graded ethanol. After microwave antigen retrieval in citrate buffer, pH 6.0, the sections were held in Tris buffer solution (TBS, 100 mM, pH 7.6). Endogenous peroxidase activity was inactivated using 3% hydrogen peroxide in methanol and endogenous biotin activity was blocked by a sequence of diluted egg white (5% in distilled water) and skimmed milk powder (5% in distilled water), all for 10 min each. The sections were incubated in mouse monoclonal antibody against PPARγ (1/400 in 1% BSA in TBS) overnight at 4°C. Antibody binding was amplified using biotin and streptavidin HRP for 10 min each and the complex was visualised using diaminobenzidine. The nuclei were lightly stained with Mayer's haematoxylin and the sections were mounted and cover slipped. An isotype IgG1 matched diluted was substituted for the antibody as negative control.

Sections were assessed microscopically for positive staining by two experienced observers. For each specimen, the positive staining extent was scored as five grades, namely, 0 ([less-than-or-eq, slant]10%), 1 ([gt-or-equal, slanted]11–25%), 2 ([gt-or-equal, slanted]26–50%), 3 ([gt-or-equal, slanted]51–75%), 4([gt-or-equal, slanted]76–90%) and 5 ([gt-or-equal, slanted]91–100%) (Armes et al, 1999). The intensity was classified into four grades: no staining, negative (−); pale brown, weak (+); brown, moderate (++) and dark brown, strong (+++). Parallel paraffin-embedded sections were stained with haematoxylin and eosin to confirm the pathologic diagnosis simultaneously.

Western blot

Preparation of ovarian tissue homogenate was performed as described previously (Ahmed et al, 2004). Each frozen ovarian specimen (100 mg) was cut into several small pieces about 3 mm in size. Then, the specimen was homogenized in Tris-HCl buffer (10 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM dithiothreitol, 1 mM orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 5 μg ml−1 aprotonin, pH 7.0) by repeated uniform strokes (approximately 6). The samples were centrifuged at 10 000 g for 20 min. The supernatant was collected and relative protein concentration was determined using Bio-Rad Protein Assay Reagent following the manufacturer's instruction. Ovarian homogenate containing equal amounts (10 μg) of protein were separated by electrophoresis on 10% sodium dodecyl sulphate (SDS)–polyacrylamide gels under nonreducing condition and transferred to nitrocellulose membranes. The membranes were probed with rabbit polyclonal anti-PPARγ (diluted 1 : 400 in 3% skim milk in TBST) followed by peroxidase-labelled donkey anti-rabbit secondary antibody (1 : 2500) and visualised by the ECL (Amersham, UK) detection system according to the manufacturer's instruction.

Statistical analysis

The extent and intensity of immunohistochemical staining between benign, borderline and high-grade ovarian tumours was determined by χ2 test. The association between the optical density (OD) of PPARγ bands determined by Western blotting in benign tumours compared to that of high-grade ovarian tumours was assessed by Student's t-test.

RESULTS

Immunohistochemical staining of PPARγ in ovarian tumour tissues

Immunohistochemical expression of PPARγ in epithelial ovarian tumours is described in Table 2 . No immunoreactivity of PPARγ was observed in normal ovarian tissues (Figure 1C). Among eight benign and 10 borderline ovarian tumours, weak PPARγ expression was present in only one tumour in each group (Figure 2A). Seven cases of grade 1 ovarian tumours were studied. Four of these showed weak staining and moderate staining was observed in three cases. Both cytoplasmic and nuclear staining was observed (Figure 2B), the distribution being approximately 60% cytoplasmic and 40% nuclear.

Figure 1
(A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARγ staining of the same (C) normal ovary (D) and grade 3 serous ovary. Blue arrows indicate nuclear PPARγ staining, while black indicates cytoplasmic ...
Figure 2
PPARγ staining of (A) benign mucinous tumour, (B) grade 1 mucinous tumour, (C) grade 2 endometrioid tumour, (D) grade 3 endometrioid tumours and (E) grade 3 serous tumour. Arrows indicate nuclear (blue) and cytoplasmic (black) PPARγ staining. ...
Table 2
Extent and intensity of PPARγ expression in normal ovaries and tumour tissues

Eight out of nine grade 2 tumours studied were positive for PPARγ and the expression varied from a score of 1 to 3 with increased demonstration of nuclear staining (Figure 2C). Nuclear staining of infiltrating macrophages was observed in one case. In all, 12 grade 3 ovarian tumours were studied and 11 of these were positive. The intensity of PPARγ staining varied but was predominantly judged to be moderate (++) (Figures 1D and 2D, E). In grade 2 and 3 tumours, staining was predominantly nuclear. Cytoplasmic staining in higher grades (grades 2 and 3) represented approximately 20% of total staining.

Overall, the immunoreactive PPARγ was present in all grades of ovarian tumours. The extent of overall staining was significantly higher in malignant ovarian tumours (grades 1, 2 and 3) compared with benign and borderline tumours (χ2=48.80, P<0.001) (Table 2). PPARγ staining in ovarian tumours was mainly localised to the cytoplasm or nuclei of tumour cells. Nuclear staining increased significantly with the grade of the tumours (80% in grade 3 compared to 40% in grade 1). Tumour stroma or endothelial cells lining the blood vessels were negative for PPARγ immunoreactivity. The intensity of PPARγ staining was also significantly higher in malignant tumours compared with benign and borderline tumours (χ2=43.93, P<0.001) (Table 2). No statistical difference in the extent or intensity of staining was observed between the different grades of tumours (grades 1, 2 and 3) (χ2=4.29, P=0.6363; χ2=1.68, P=0.79) (Table 2).

Expression of PPARγ in ovarian tumour tissues using Western blot analysis

The expression of PPARγ in human ovarian tumour tissues was also evaluated by Western blot analyses (Figure 3). The expression of PPARγ in ovarian tumour tissues was significantly higher than in normal ovaries and benign ovarian tumours (P<0.01) (Figure 3A). However, no difference in the expression of PPARγ in normal ovaries and benign ovarian tumours was demonstrated (P>0.05) (Figure 3C).

Figure 3
Western blot analyses of PPARγ expression in normal ovary, benign and grade 3 ovarian tumours. (A) Western blot was carried out as described in the Material and Methods section. A total of 10 μg of protein was loaded in a total ...

DISCUSSION

The sustainability of a malignant tumour requires multiple cellular events by which the cancer cells acquire growth factor independence, escape cellular apoptosis mechanisms, create a self-sustaining environment and escape the neighbouring barriers by migrating and colonising to a distant site (Hanahan and Weinberg, 2000). These events require the expression/overexpression and activation of molecules not generally requisite for normal cellular functions. The initial indication that the PPARs are involved in the aetiology of cancer was the isolation of PPARα as the mediator of the tumour-promoting effect of peroxisome proliferators, compounds that cause heptocellular carcinoma in rodents (Corton et al, 2000). PPARα has been shown to be expressed in colon tumours and overexpressed in breast and prostate tumours (Collett et al, 2000; Roberts-Thomson and Snyderwine, 2000). PPARβ levels are also elevated in colon and head and neck cancer (Gupta et al, 2000; Jaeckel et al, 2001) and the absence of PPARβ reduces tumour growth in colon cancer (Park et al, 2001). Although PPARγ is expressed at low levels in normal colonic and breast ductal epithelium, it is significantly increased in breast and prostate carcinoma. The expression of this receptor has not been reported in ovarian carcinoma but has been shown in normal ovaries (Lambe and Tugwood, 1996). In this study, we report the expression of PPARγ in different pathological grades and subtypes of ovarian carcinoma and discuss its possible function with the progression of the disease.

We report for the first time that ovarian tumours express PPARγ. Weak to moderate expression of PPARγ by immunohistochemistry was observed in almost all ovarian tumours studied. As shown in Table 2 and Figure 1, immunohistochemical staining showed no PPARγ expression in normal ovarian tissues. Out of eight benign and 10 borderline tumours, only one in each group stained positive for PPARγ expression. Weak to moderate staining was observed in grade 1 ovarian tumours (Figure 2B), and the staining was localised to both cytoplasmic and nuclear areas of the cells. Compared to benign and borderline tumours, the extent of staining was, however, significantly increased in grade 3 ovarian tumours, with immunoreactivity for PPARγ being mostly present in the nuclear region (Figures 1 and and2).2). Western blotting analyses demonstrated significant enhancement in the expression of PPARγ in grade 3 ovarian tumours compared to benign ovarian tumours and normal ovaries (Figure 3). The basal expression of PPARγ in normal ovarian tissues and benign ovarian tumours may have been attributed by the increased immunosensitivity of Western blotting technique compared to immunohistochemistry.

The results from our study are consistent with those of other studies performed in other cancers. Very weak immunohistochemical staining of PPARγ was shown in benign prostatic hyperplasia and normal prostate tissues, whereas significant enhancement in the expression of immunoreactive PPARγ was observed in malignant prostate tissues (Park et al, 2001). PPARγ expression was shown to be higher in high-grade bladder cancer compared to low-grade cancer (Yoshimura et al, 2003). Irrespective of the differentiation status of the tumour, strong expression of immunoreactive PPARγ was observed in surgically resected human gastric cancer tissues (Sato et al, 2000).

In contrast, in some cases of cancer, the expression of PPARγ decreases with the histological grade of the tumour. In full-term normal placenta, PPARγ is strongly expressed in the nuclei of the syncytiotrophoblast, extravillous cytotrophoblast of cell islands and cell columns, whereas in choriocarcinoma, only a few trophoblastic cells show weak staining for PPARγ (Capparuccia et al, 2002). Well-differentiated lung adenocarcinomas present increased frequency for PPARγ expression compared with moderately and poorly differentiated ones (Theocharis et al, 2002). The expression of PPARγ protein is decreased in oesophageal cancer tissues compared with normal oesophageal squamous epithelium (Terashita et al, 2002). Hence, considering the diversity of human cancer, the expression of PPARγ is possibly dependent on tissue specificity and/or the mutational events (as in the case of colon cancer) (Ikezoe et al, 2001) that are requisite for cancer development.

The growth inhibitory and differentiation roles of PPARγ have been shown in several cancers (Demetri et al, 1999). The immunohistochemical expression of PPARγ during the progression of ovarian cancer can be related to the growth-promoting role of PPARγ previously shown in certain cancer (Mueller et al, 2000). In the case of thyroid follicular cancer, a chromosomal translocation and fusion of PAX8 gene with PPARγ results in a malignant phenotype, suggesting a link of PPARγ to cancer growth (Dwight et al, 2003). In the Min mouse model of APC deficiency, ligands for PPARγ can increase colon tumour growth (Lefebvre et al, 1998). In another study, loss of PPARγ was shown not to affect mammary development and propensity for tumour formation but resulted in reduced fertility (Cui et al, 2002). Overall, ligand activation of PPARγ in tumour models can result in diversified functional outcome (Leung et al, 2004) and a better understanding of the exact role of PPARγ in cancer needs to be determined. In particular, the mechanism of differentiation of cancers is incompletely understood and an insight into this process would undoubtedly lead to new therapeutic targets.

The anti-inflammatory response of PPARγ in association with NF-κB has recently been identified (Kelly et al, 2004). In addition, PPARγ ligands have been shown to inhibit transcriptional activation of COX-2 in human epithelial cells (Badawi et al, 2004). In certain cancer cells, ligand activation of PPARγ results in the inhibition of the release of inflammatory cytokines by cancer cells (Leung et al, 2004). These results may help to explain the shuttling of PPARγ expression from the cytoplasm to nucleus with the progression of ovarian carcinoma. As ovarian cancer progresses, tumour cells are more likely to be exposed to inflammatory cytokines secreted by cancer cells themselves and infiltrating leucocytes present in the peritoneum. Whether this increased exposure of ovarian tumour cells to the inflammatory cytokines result in the activation of PPARγ and subsequent cytoplasmic translocation to the nucleus is yet to be determined.

Taken together, our results indicate that PPARγ may play a role in the onset and progression of ovarian cancer. Further research need to investigate the prognostic significance of PPARγ expression in ovarian carcinoma and whether therapeutic administration of ligands for this receptor may have clinical potential for the treatment of the disease.

Acknowledgments

We thank the Cancer Council of Victoria, the Rotary Club of Williamstown, Ovcare and Jigsaw Women's Fashion Company and the Jack Brockhoff Foundation, Australia for supporting this work. Dr GY Zhang received a Chinese government scholarship during the course of the study.

References

  • Ahmed N, Oliva K, Rice GE, Quinn MA. Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res. 2004;10:2415–2420. [PubMed]
  • Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011–2017. [PubMed]
  • Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I. Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun. 2004;315:497–501. [PubMed]
  • Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res. 2004;64:1181–1189. [PubMed]
  • Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435. [PubMed]
  • Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med. 2003;127:1121–1123. [PubMed]
  • Burgermeister E, Tencer L, Liscovitch M. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene. 2003;22:3888–3900. [PubMed]
  • Capparuccia L, Marzioni D, Giordano A, Fazioli F, De Nictolis M, Busso N, Todros T, Castellucci M. PPARgamma expression in normal human placenta, hydatidiform mole and choriocarcinoma. Mol Hum Reprod. 2002;8:574–579. [PubMed]
  • Choi KC, Auersperg N. The ovarian surface epithelium: simple source of a complex disease. Minerva Ginecol. 2003;55:297–314. [PubMed]
  • Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res. 2000;6:3241–3248. [PubMed]
  • Corton JC, Lapinskas PJ, Gonzalez FJ. Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res. 2000;448:139–151. [PubMed]
  • Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner KU, Hennighausen L. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility J Biol Chem 2002. 27717830–17835.17835Epub 2002 Mar 7 [PubMed]
  • Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999;96:3951–3956.
  • Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C, Zedenius J. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:4440–4445. [PubMed]
  • Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab. 2004;286:E201–E207. [PubMed]
  • Gauthier A, Vassiliou G, Benoist F, McPherson R. Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma J Biol Chem 2003. 27811945–11953.11953Epub 2003 Jan 27 [PubMed]
  • Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA. 2000;97:13275–13280.
  • Han S, Inoue H, Flowers LC, Sidell N. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res. 2003;9:4627–4635. [PubMed]
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. [PubMed]
  • Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 2000;60:5494–5498. [PubMed]
  • Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H, Koeffler HP. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res. 2001;61:5307–5310. [PubMed]
  • Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer Mol Cell Proteomics 2004. 3355–366.366Epub 2004 Feb 5 [PubMed]
  • Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, Tsue TT, Sanford TR. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1253–1259. [PubMed]
  • Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer. 2003;106:752–757. [PubMed]
  • Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA Nat Immunol 2004. 5104–112.112Epub 2003 Dec 21 [PubMed]
  • Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421–424. [PubMed]
  • Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355–7359.
  • Lambe KG, Tugwood JD. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem. 1996;239:1–7. [PubMed]
  • Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053–1057. [PubMed]
  • Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut. 2004;53:331–338. [PMC free article] [PubMed]
  • Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol. 1998;10:384–391. [PubMed]
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990–10995.
  • Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 2001;98:2598–2603.
  • Pignatelli M, Cocca C, Santos A, Perez-Castillo A, Jiang WG, Douglas-Jones A, Mansel RE. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene. 2003;22:5446–5450. [PubMed]
  • Roberts-Thomson SJ, Snyderwine EG. Characterization of peroxisome proliferator-activated receptor alpha in normal rat mammary gland and 2-amino-l-methyl-6-phenylimidazo[4, 5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets. Toxicol Lett. 2000;118:79–86. [PubMed]
  • Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer. 2000;83:1394–1400. [PMC free article] [PubMed]
  • Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ, Ham J, Kang H, Park MG, Steffensen KR, Stulnig TM, Gustafsson JA, Park SD, Kim JB. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2004;24:3430–3444. [PMC free article] [PubMed]
  • Silverberg S. Histopathologic grading of ovarian carcinoma: a review an proposal. Int J Gynecol Pathol. 2000;19:7–15. [PubMed]
  • Smith MR, Kantoff PW. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs. 2002;20:195–200. [PubMed]
  • Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, Kudo J, Konishi S, Kato J, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y, Fujii Y. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol. 2002;32:238–243. [PubMed]
  • Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer. 2002;36:249–255. [PubMed]
  • Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia. 2000;2:483–490. [PMC free article] [PubMed]
  • Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PE, Jones JG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC, Pestell RG, Jiang WG, Douglas-Jones A, Mansel RE. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003;23:6159–6173. [PMC free article] [PubMed]
  • Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res. 2003;9:3198–3203. [PubMed]
  • Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H, Nakatani T. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104:597–602. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK